Tempus AI (NASDAQ:TEM) Trading Down 0.5% – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price fell 0.5% during mid-day trading on Friday . The stock traded as low as $34.82 and last traded at $37.30. 1,160,993 shares changed hands during trading, a decline of 65% from the average session volume of 3,336,246 shares. The stock had previously closed at $37.49.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital upped their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Stock Performance

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company’s 50-day moving average price is $48.28 and its two-hundred day moving average price is $47.13.

Insider Buying and Selling at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Ryan Fukushima sold 120,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This represents a 10.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 865,041 shares of company stock worth $35,917,673 over the last 90 days.

Institutional Trading of Tempus AI

Several institutional investors have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the third quarter worth about $30,000. Geode Capital Management LLC grew its position in Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the last quarter. Vestor Capital LLC purchased a new position in shares of Tempus AI in the third quarter worth $153,000. The Manufacturers Life Insurance Company boosted its position in Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after buying an additional 2,765 shares during the period. Finally, Stifel Financial Corp bought a new stake in Tempus AI in the 3rd quarter worth $218,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.